# Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

> **NCT04994717** · PHASE3 · RECRUITING · sponsor: **Amgen** · enrollment: 304 (estimated)

## Conditions studied

- Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** Low-intensity chemotherapy regimen
- **DRUG:** SOC chemotherapy regimen

## Key facts

- **NCT ID:** NCT04994717
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-02
- **Primary completion:** 2029-09-07
- **Final completion:** 2031-07-01
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04994717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04994717, "Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT04994717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*